Guillermo Garcia-Manero, MD, on IRAK4, Emavusertib

By Leah Sherwood - Last Updated: November 15, 2022

Guillermo Garcia-Manero, MD, of the Department of Leukemia at MD Anderson Cancer Center, discusses why the novel drug emavusertib, an IRAK4 inhibitor, is a potential treatment option for patients with hematologic malignancies.

Advertisement
Editorial Board

Advertisement